

**TOWARDS NOVEL APPROACHES FOR ENCOUNTERING
AGGREGATION OF BIOLOGICALLY RELEVANT
PROTEINS**

SAURABH GAUTAM



**DEPARTMENT OF CHEMISTRY
INDIAN INSTITUTE OF TECHNOLOGY DELHI
OCTOBER 2016**

© Indian Institute of Technology Delhi (IITD), New Delhi, 2016

**TOWARDS NOVEL APPROACHES FOR ENCOUNTERING
AGGREGATION OF BIOLOGICALLY RELEVANT
PROTEINS**

by

SAURABH GAUTAM

Department of Chemistry

Submitted

in fulfilment of the requirements of the degree of Doctor of Philosophy

to the



INDIAN INSTITUTE OF TECHNOLOGY DELHI

OCTOBER 2016

***“Knowledge can only be got in one way, the way of experience;
there is no other way to know”***

— Swami Vivekananda

CERTIFICATE

This is to certify that the thesis titled “**Towards Novel Approaches for Encountering Aggregation of Biologically Relevant Proteins**” being submitted by **Mr. Saurabh Gautam** to the Indian Institute of Technology Delhi for the award of degree of **Doctor of Philosophy** is a record of bonafide research work carried out by him. Mr. Saurabh Gautam has worked under my guidance and supervision and has fulfilled the requirements for the submission of this thesis, which to my knowledge has reached the requisite standard.

The results contained in this thesis are original and have not been submitted, in part or full, to any other University or Institute for the award of any other degree or diploma.

Dr. Pramit K. Chowdhury
Associate Professor
Department of Chemistry
Indian Institute of Technology Delhi
Hauz Khas, New Delhi 110016, India

ACKNOWLEDGEMENTS

It is a great pleasure for me to write the acknowledgement for my Ph.D. thesis which arose out of years of research work carried out at IIT Delhi. As is the case with any accomplishment, I have also worked for this thesis with different people whose contribution in various ways deserves special mention. I feel honoured while conveying my gratitude to all of them in my humble acknowledgement.

*In the first place I would like to express my special appreciation and thanks to my supervisor **Dr. Pramit K. Chowdhury**, he has been a tremendous mentor for me. I would like to thank him for encouraging my research and for allowing me to grow as a researcher. His advice on both research as well as on my career have been priceless. Without his constant guidance, I could not have finished this thesis. I am highly indebted to him for providing help, support and all the opportunities not only during research but also during critical phase of my career and countless other times.*

*I would also like to thank my research committee members, **Dr. Nalin Pant, Dr. Shashank Deep and Dr. Bishwajit Kundu** (Kusuma School of biological Sciences, IIT Delhi) for serving as my committee members, and for their brilliant comments and suggestions.*

*I would like to thank all the past and present **Heads of the Department of Chemistry** at IIT Delhi for providing me necessary facilities required for the completion of this research work. I would also like to thank **DRC chairperson**, all the **faculty**, and **staff members** of the Department of Chemistry.*

*I am thankful to **Council of Scientific and Industrial Research (CSIR)** for the financial support provided to me during the course of research.*

*This thesis would be incomplete without words of gratitude to all my lab members who helped me to make this thesis possible. To begin with, I would like to thank my labmates **Dr. Ashima Malik, Jayanta, Saikat, Sanjib, Priyanka, Sandip, Tripti** and all the **M.Sc., M.Tech.** and project students. Their kind support and guidance have been of great value in this work.*

I would also like to thank the lab members of Dr. Shashank Deep and Dr. Bishwajit Kundu's groups for always being supportive and helpful.

*I am also extremely grateful to **Dr. Anurag Sharma** (Amity University, Gurgaon) and **Dr. Gulam Mohamad Rather** (Robert Wood Johnson Medical School, New Jersey) for their help during my early days at IIT Delhi.*

*A line of appreciation of course goes to some of my dearest friends including **Yogendra, Sumit, Satyendra** and all my batchmates for their invariable support and indispensable help in achieving this feat.*

*I would also like to thank all the members of our own **Ph.D. football club AAFC**. We always found time out of our research work and busy schedules to play football which always used to refresh us. This is the right moment to mention about my antagonizing (fans of FC Barcelona and Real Madrid are always rivals in football!!) but constructive discussions about football with **Soumen** and **Tanmoy**. These discussions always cheered me up.*

*A special thanks to my family. Words cannot express how grateful I am to my **mother-in law, father-in-law, mother, father** and **my siblings** for all of the sacrifices that you've made on my behalf. Your prayer for me was what sustained me thus far. At the end I would like to express appreciation to my beloved wife **Priyanka** who spent sleepless nights with me and was always my support in the moments when there was no one to answer my queries. My sincere apologies to those whom I could not mention due lack of space, but thank them equally.*

Saurabh Gautam

ABSTRACT

The thesis entitled “**Towards novel approaches for encountering aggregation of biologically relevant proteins**” describes various novel approaches for overcoming protein aggregation. Major focus has been on providing therapeutic alternatives for protein aggregation diseases such as Parkinson’s disease wherein α -synuclein protein undergoes aggregation and forms amyloid fibrils in brain tissues. The thesis also describes about the strategies for refolding proteins using smart polymers from aggregates known as inclusion bodies formed during recombinant protein expression in research laboratories and industrial settings.

Chapter 1 (Introduction) introduces the problems and challenges in the field of protein aggregation and associated diseases being investigated by researchers globally and in the context of this thesis. The chapter also gives an account of the research work that has been carried out by various research groups to understand and overcome protein aggregation using various strategies. The chapter further discusses macromolecular crowding, that has also been shown to modulate protein aggregation.

Chapter 2 (Materials and Methods) describes various materials and methods used for carrying out experiments described in this thesis. The chapter also provides details on the expression, isolation and purification of α -synuclein and other recombinant proteins producing inclusion bodies. Different techniques and methodologies used for characterizing proteins and protein aggregates have been summarized.

Chapter 3 entitled “ **β -Cyclodextrin and curcumin, a potent cocktail for disaggregating and/or inhibiting amyloids: A case study with α -synuclein**” describes the study on the influence of the combination of β -CD (β -cyclodextrin) and curcumin on the aggregation of α -synuclein. Aggregation of α -synuclein has been implicated in Parkinson’s disease (PD). While many compounds are known to inhibit α -synuclein aggregation, dissolution of aggregates into their constituent monomers cannot be readily achieved. In this study, using a range of techniques, we have shown that an optimized cocktail of curcumin and β -cyclodextrin, at appreciably low concentrations, not only inhibited aggregation but also broke up the preformed aggregates almost completely. We propose that these compounds exhibit synergy in their action and thus provide us with the exciting prospect of working toward the development of a suitable drug candidate for prevention and treatment of PD.

Chapter 4 entitled “**Polyphenols in combination with β -cyclodextrin can inhibit and disaggregate α -synuclein amyloids under cell mimicking conditions: A promising**

therapeutic alternative” examines the effects of four naturally occurring polyphenols in combination with β -cyclodextrin (β -CD) on the aggregation of α -synuclein in the presence of macromolecular crowding agents. Parkinson’s disease is characterized by the presence of insoluble and neurotoxic aggregates (amyloid fibrils) of an intrinsically disordered protein α -synuclein. Our results reveal that even at sub-stoichiometric concentrations of the individual components, the polyphenol- β -CD combination(s) not only inhibited the aggregation of the proteins but was also effective in disaggregating preformed fibrils. Curcumin was found to be the most efficient, followed by baicalein with (-)-epigallocatechin gallate and resveratrol coming in next, the latter two exhibiting very similar effects. Our results suggest that the efficiency of curcumin results from a balanced composition of the phenolic -OH groups, benzene rings and flexibility. The uniqueness of β -CD was reinforced by the observation that none of the other cyclodextrin variants [α -CD and HP- β -CD] used were as effective, in spite of these possessing better water solubility. Moreover, the fact that the combinations remained effective under conditions of macromolecular crowding suggests that these have the potential to be developed into viable drug compositions in the near future. MTT assays on cell viability independently confirmed this hypothesis wherein these combinations (and the polyphenols alone too) appreciably impeded the toxicity of the prefibrillar α -synuclein aggregates on the mouse neuroblastoma cell lines (N2a cells).

Chapter 5 entitled “**Anti-amyloidogenic effect of a chemical chaperone in combination with β -cyclodextrin and polyphenols: Further improving the polyphenol- β -CD combination**” shows the effect of an osmolyte on the modulation of protein aggregation in association with polyphenol- β -CD combination. The aim of this chapter was to further improve the polyphenol- β -CD combination by incorporating sucrose, a well known osmolyte. While sucrose by itself could only inhibit aggregation at a concentration of 500 mM, however in combination with polyphenol- β -CD mixture, its effective concentration came down to 3.5 mM. Sucrose (3.5 mM) with polyphenol- β -CD combination was highly effective in curbing the aggregation of α -synuclein. This study showed that the presence of sucrose is very important in the polyphenol- β -CD combination to enhance their effectiveness and overcome the shortcomings (e.g. high dosage requirement).

Chapter 6 entitled “**Examining the universality of the combination of polyphenols, β -CD and sucrose**” investigates the universality of the combinations of polyphenol- β -CD and polyphenol- β -CD-osmolyte in terms of their effectiveness on other proteins that have definite three dimensional structures in their native states. Studies were performed on two different globular proteins: β -lactoglobulin (from bovine milk) and lysozyme (from chicken

egg white). β -Lactoglobulin showed faster kinetics of aggregation with an increase in the concentration of all the crowding agents up to 200 g/L. On the contrary, lysozyme followed a reversed path and showed a decrease in the aggregation kinetics under similar conditions. The polyphenol- β -CD and osmolyte-polyphenol- β -CD combinations were able to inhibit the aggregation and disaggregate preformed aggregates of these two proteins. However, the concentration of these molecules required was different in case of different proteins. This study thus proves the potency of the concoction and strives to establish its overall effectiveness for protein aggregates in general.

Chapter 7 entitled “**Smart polymer mediated purification and recovery of active proteins from inclusion bodies**” discusses the effect of stimuli sensitive smart polymers as pseudochaperonins on the refolding various highly aggregation prone recombinant proteins forming inclusion bodies. Obtaining correctly folded proteins from inclusion bodies of recombinant proteins expressed in bacterial hosts requires solubilization with denaturants and a refolding step. Aggregation competes with the second step. Refolding of eight different proteins was carried out by precipitation with smart polymers. A high throughput refolding screen based upon fluorescence emission maximum around 340 nm (for correctly folded proteins) was developed to identify the suitable smart polymer. The proteins could be dissociated and recovered after the refolding step. The refolding could be scaled up and high refolding yields in the range of 8 mg/L (for CD4D12, the first two domains of human CD4) to 58 mg/L (for malETrx, thioredoxin fused with signal peptide of maltose binding protein) were obtained. The refolded proteins were characterized using fluorescence spectroscopy, circular dichroism (CD) spectroscopy, melting temperature (T_m) analyses, and surface hydrophobicity measurements using ANS (8-anilino-1-naphthalene sulfonic acid) fluorescence. Biological activity assay for thioredoxin and fluorescence based assay in case of maltose binding protein (MBP) were also carried out to confirm correct refolding.

Chapter 8 entitled “**Conclusion and future prospects**” represents the conclusions drawn from all the studies mentioned above and the future prospects of the work carried out so far in this thesis. The studies described in this thesis have opened up opportunities for the follow up work which include: expanding the repertoire of polyphenols and encapsulators; understanding the mechanism of action of such combinations in greater detail; and use of other proteins related with neurodegenerative diseases for studying the effectiveness of such combinations.

TABLE OF CONTENTS

Title	Page No.
Certificate	(i)
Acknowledgements	(ii)
Abstract	(iv)
Table of Contents	(vii)
List of Figures	(xii)
List of Tables	(xx)
Chapter 1: Introduction	
1.1 Introduction to protein aggregation	1
1.2 Types of protein aggregates	6
1.3 Mechanism of protein aggregation	9
1.4 Effect of macromolecular crowding on protein aggregation	12
1.5 Therapeutic interventions of protein aggregation diseases	16
1.5.1 Peptide based therapeutics	17
1.5.2 Therapeutics based on amyloid detection dyes	19
1.5.3 Polyphenols	22
1.5.4 Chelating agents as therapeutics	26
1.5.5 Osmolytes	27
1.5.6 Other molecules	29
1.6 Role of smart polymers in protein aggregation	33
1.7 Present research problem in the context of this thesis	34
1.8 Organization of the thesis	36
1.9 References	39
Chapter 2: Materials and Methods	
2.1 Materials	69
2.2 Expression, isolation and purification of recombinant proteins	69
2.2.1 Expression, isolation and purification of human α -synuclein	70
2.2.2 Expression, isolation and solubilization of recombinant proteins forming	70

inclusion bodies	
2.3 Preparation of solutions of polyphenols	72
2.4 Preparation of solutions of smart polymers	72
2.4.1 Preparation of Eudragit solution	72
2.4.2 Preparation of cationic starch solution	73
2.4.3 Preparation of alginate solution	73
2.5 Spectroscopic Measurements	73
2.5.1 UV-visible spectroscopy	73
2.5.2 Fluorescence spectroscopy	74
2.5.2.1 <i>ANS binding measurements using fluorescence spectroscopy</i>	76
2.5.2.2 <i>Curcumin binding measurements using fluorescence spectroscopy</i>	76
2.5.3 Circular dichroism spectroscopy	77
2.5.4 Dynamic light scattering (DLS)	81
2.6 PAGE (Polyacrylamide Gel Electrophoresis)	82
2.6.1 Native-PAGE	83
2.6.2 SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis)	83
2.7 Transmission electron microscopy (TEM)	83
2.8 Size exclusion chromatography (SEC)	84
2.9 Estimation of protein concentrations	86
2.10 Fibril formation assay	86
2.10.1 Data fitting for aggregation kinetics	88
2.11 Cytotoxicity assays	89
2.12 High-throughput screening of the smart polymer in 96-well plate format for protein refolding	90
2.13 Refolding of recombinant proteins from inclusion bodies using smart polymers	90
2.13.1 Refolding of mutants of CcdB (F17P and M97K), malETrx and CD4D12 from inclusion bodies with Eudragit L-100	90
2.13.2 Refolding of mutants of MBP (224D and 264D) from inclusion bodies with cationic starch	91
2.13.3 Refolding of two antibody fragments (ScFv b12 and ScFab b12) from inclusion bodies with alginate	92
2.14 Activity assays	93

2.14.1 Assay for lysozyme	93
2.14.2 Assay for thioredoxin	93
2.14.3 Maltose binding assay for maltose binding protein (MBP)	93
2.15 References	95
Chapter 3: β-Cyclodextrin and curcumin, a potent cocktail for disaggregating and/or inhibiting amyloids: A case study with α-synuclein	
3.1 Introduction	100
3.2 Results and discussion	101
3.3 References	117
Chapter 4: Polyphenols in combination with β-cyclodextrin can inhibit and disaggregate α-synuclein amyloids under cell mimicking conditions: A promising therapeutic alternative	
4.1 Introduction	123
4.2 Results	128
4.2.1 Aggregation	128
4.2.2 Inhibition of aggregation	132
4.2.3 Disaggregation	136
4.2.4 Secondary structure of α -synuclein	138
4.2.5 Size exclusion chromatography (SEC) analyses	141
4.2.6 Transmission electron microscopy (TEM)	144
4.2.7 Role of β -cyclodextrin (β -CD)	147
4.2.8 Stoichiometry between protein and polyphenols/ β -CD combination is also important	148
4.2.9 Cytotoxicity assays	149
4.3 Discussion	151
4.4 Conclusion	159
4.5 References	161
Chapter 5: Anti-amyloidogenic effect of a chemical chaperone in combination with β-cyclodextrin and polyphenols: Further improving the polyphenol-β-CD combination	
5.1 Introduction	168
5.2 Results	169
5.2.1 Effect of the osmolytes alone on the aggregation of human α -synuclein	169

5.2.2	Effect of osmolytes in combination with curcumin and β -CD on the aggregation of human α -synuclein	171
5.2.3	Disaggregation of preformed amyloid fibrils of human α -synuclein by the optimized combination of sucrose, curcumin and β -CD	177
5.2.4	Secondary structural analysis and size exclusion chromatography (SEC) of human α -synuclein	178
5.2.5	Morphological analysis of human α -synuclein using transmission electron microscopy (TEM)	180
5.2.6	Effect of sucrose in combination with EGCG and β -CD on protein aggregation	181
5.2.7	Further enhancing the sucrose concentration does not significantly alter the stoichiometry with polyphenols and β -CD for inhibiting protein aggregation	182
5.3	Discussion	184
5.4	Proposed mechanism of action	186
5.4.1	Inhibition of protein aggregation	187
5.4.2	Disaggregation of preformed aggregates	188
5.4.2.1	<i>Initiation</i>	188
5.4.2.2	<i>Interaction</i>	188
5.4.2.3	<i>Dissociation</i>	190
5.4.2.4	<i>Sequestration</i>	191
5.5	References	193
Chapter 6: Examining the universality of the combination of polyphenols, β-CD and sucrose		
6.1	Introduction	199
6.2	Results	201
6.2.1	Aggregation of the globular proteins (β -lactoglobulin and lysozyme)	201
6.2.2	Effect of curcumin- β -CD combination on the aggregation of globular proteins	205
6.2.3	Effect of sucrose in combination with curcumin and β -CD on aggregation	209
6.2.4	Disaggregation of preformed aggregates of β -lactoglobulin and lysozyme	212
6.2.5	Replacing curcumin in the combination with EGCG	216
6.2.6	Studying the interaction of proteins with curcumin	216
6.2.7	Inhibition of aggregation upon sucrose concentration enhancement	220
6.3	Discussion	222

6.4 References	229
Chapter 7: Smart polymer mediated purification and recovery of active proteins from inclusion bodies	
7.1 Introduction	235
7.2 Results	237
7.2.1 High-throughput screening of the affinity ligand (smart polymer) in 96-well plate format for appropriate refolding of the proteins	238
7.2.2 Refolding of two mutants of CcdB (CcdB-F17P and M97K) from inclusion bodies	243
7.2.2.1 <i>Characterization of refolded CcdB mutants</i>	249
7.2.3 Refolding of malETrx and human CD4D12 from inclusion bodies	253
7.2.4 Refolding of two mutants of MBP (MBP224D and 264D) from inclusion bodies	257
7.2.5 Refolding of two antibody fragments (ScFv b12 and ScFab b12) from inclusion bodies	258
7.2.6 Refolding yields	260
7.2.7 Understanding the role of smart polymers in refolding	262
7.3 Discussion	264
7.4 References	267
Chapter 8: Conclusion and future prospects	274
ANNEXURE I: Supplementary Information for Chapter 4	279
ANNEXURE II: Supplementary Information for Chapter 5	289
ANNEXURE III: Supplementary Information for Chapter 6	291
ANNEXURE IV: Supplementary Information for Chapter 7	294
Brief Bio-Data of the Author	296

LIST OF FIGURES

Figure No.	Figure Title	Page No.
Chapter 1		
1.1	Protein aggregation and its fate inside the cells	4
1.2	Structural diversity of precursor states for amyloid fibrils	8
1.3	Schematic diagram representing mechanism of protein aggregation and amyloid formation	11
1.4	Chemical structures of various commonly used synthetic crowding agents to mimic the intracellular environment	13
1.5	Chemical structure of congo red	20
1.6	Chemical structures of congo red derivatives as imaging probes for tracking protein aggregation and neurodegenerative diseases	23
Chapter 2		
2.1	Jablonski diagram describing the various electronic states of molecules, the processes competing with fluorescence and possible transitions between singlet and triplet states	75
2.2	Origin of the circular dichroism effect	78
2.3	Separation of molecules based on their size by SEC	85
Chapter 3		
3.1	Structures of curcumin and β -cyclodextrin	101
3.2	Aggregation of α -synuclein (35 μ M) in the presence of ethanol (20%, v/v) and FeCl ₃ (0.1 mM)	102
3.3	Effects of curcumin and β -CD on the aggregation of α -synuclein monitored using ThT fluorescence ($\lambda_{ex} = 430$ nm and $\lambda_{em} = 485$ nm)	103
3.4	Effects of curcumin and β -CD on the aggregation of α -synuclein monitored using congo red absorbance at 540 nm	104
3.5	Inhibition of aggregation of α -synuclein as determined by circular dichroism spectroscopy	105
3.6	Native PAGE of α -synuclein	107
3.7	Disaggregation of preformed aggregates of α -synuclein monitored using ThT fluorescence ($\lambda_{ex} = 430$ nm and $\lambda_{em} = 485$ nm)	109

3.8	Disaggregation of preformed aggregates of α -synuclein monitored using congo red absorbance at 540 nm	109
3.9	Disaggregation of aggregates of α -synuclein formed after 12 hrs before and after incorporation of the combination of β -CD (10 μ M) and curcumin (5 μ M)	110
3.10	Circular dichroism spectra of α -synuclein disaggregated by the combination of β -CD (10 μ M) and curcumin (5 μ M) after initial aggregation for different time intervals	111
3.11	TEM images of α -synuclein showing the inhibition of aggregation by the curcumin- β -CD combination	112
3.12	TEM images of aggregated α -synuclein before and after incorporation of the combination of β -CD (10 μ M) and curcumin (5 μ M)	112
3.13	TEM images of aggregated α -synuclein before and after incorporation of either β -CD or curcumin only	113
3.14	SEC analysis of α -synuclein	114
3.15	Effect of the combination of β -CD (10 μ M) and curcumin (5 μ M) on the aggregation of α -synuclein in different solvent compositions	116
3.16	Disaggregation of pre-formed aggregates of α -synuclein	117
3.17	TEM images of α -synuclein aggregated in buffer before and after incorporation of the combination of β -CD (10 μ M) and curcumin (5 μ M)	117
Chapter 4		
4.1	Primary structure of α -synuclein showing three distinct regions, their roles and the corresponding number of amino acid residues	123
4.2	Chemical structures of the four different polyphenols [curcumin, resveratrol, baicalein and (–)-epigallocatechin gallate (EGCG)], β -cyclodextrin (β -CD) and two types of macromolecular crowding agents (Dextran and Ficoll) used in this study	127
4.3	Aggregation profiles of α -synuclein monitored using ThT fluorescence ($\lambda_{\text{ex}} = 430$ nm and $\lambda_{\text{em}} = 485$ nm) in the presence of different concentrations of the macromolecular crowding agents namely, Dextran 40, Dextran 6 and Ficoll 70: (Column (a)) in the absence of ethanol and (Column (b)) presence of 7.5% (v/v) ethanol	129
4.4	Aggregation of α -synuclein in the presence of Dextran 40 (100 g/L) as a macromolecular crowding agent with different concentrations of ethanol monitored using	131

4.5	Effect of different polyphenols at various concentrations on the aggregation of α -synuclein using ThT fluorescence ($\lambda_{\text{ex}} = 430$ nm and $\lambda_{\text{em}} = 485$ nm) in the presence of Dextran 40 (100 g/L) as the macromolecular crowding agent	132
4.6	Effect of different concentrations of β -CD on the aggregation of α -synuclein using ThT fluorescence ($\lambda_{\text{ex}} = 430$ nm and $\lambda_{\text{em}} = 485$ nm) in the presence of Dextran 40 (100 g/L) as a macromolecular crowding agent	134
4.7	Effect of different polyphenols in combination with β -CD on the aggregation of α -synuclein using ThT fluorescence ($\lambda_{\text{ex}} = 430$ nm and $\lambda_{\text{em}} = 485$ nm) in the presence of Dextran 40 (100 g/L) as a macromolecular crowding agent: (I) with and (II) without ethanol (7.5%, v/v)	135
4.8	Disaggregation of preformed aggregates of α -synuclein in the presence and absence of different macromolecular crowding agents: (I) with and (II) without ethanol (7.5%, v/v)	137
4.9	Dose dependent disaggregation of preformed aggregates of α -synuclein by increasing concentrations of: (a) curcumin with β -CD, (b) resveratrol with β -CD, (c) baicalein with β -CD and (d) EGCG with β -CD	139
4.10	CD spectra showing: (a) aggregation, (b) inhibition of aggregation, and (b) disaggregation of preformed aggregates of α -synuclein by curcumin (7.5 μ M) with β -CD (15 μ M); resveratrol (15 μ M) with β -CD (30 μ M); baicalein (10 μ M) with β -CD (20 μ M) and EGCG (10 μ M) with β -CD (20 μ M)	140
4.11	SEC analyses showing the elution profile of α -synuclein	142
4.12	SEC analysis showing elution profiles for inhibition of aggregation of α -synuclein by: (a) curcumin & β -CD and (b) resveratrol & β -CD; baicalein & β -CD and EGCG & β -CD	143
4.13	TEM images of α -synuclein. Aggregated α -synuclein in the presence of: (a) Dextran 40, (b) Dextran 6 and (c) Ficoll 70.	145
4.14	TEM images showing the disaggregation of preformed aggregates of α -synuclein in the presence of curcumin (7.5 μ M) with β -CD (15 μ M) at different time intervals of (a) 0 min, (b) 60 min, (c) 120 min, (d) 180 min (e) 210 min and (f) 240 min	146
4.15	Effect of different cyclodextrins and polyphenols on the aggregation of α -synuclein monitored using ThT fluorescence ($\lambda_{\text{ex}} = 430$ nm and $\lambda_{\text{em}} = 485$ nm)	147
4.16	(a) Aggregation profile of increasing concentrations of α -synuclein in the presence of the fixed optimized concentration of curcumin (7.5 μ M) with β -CD (15 μ M) and (b) effect of higher concentration of curcumin (20 μ M) and β -CD (100 μ M) on the aggregation of 100 μ M α -synuclein	149

4.17	MTT reduction assay after 12 hours incubation of N2a cells showing percentage viability in the presence or absence of α -synuclein prefibrillar aggregates (α -synuclein (P))	150
Chapter 5		
5.1	Effect of different concentrations of two osmolytes (glucose and sucrose) on the aggregation of α -synuclein	170
5.2	Effect of different concentrations of osmolytes in the presence of curcumin (1.25 μ M) and β -CD (2.5 μ M) on the aggregation of α -synuclein	172
5.3	Effect of sucrose in combination with curcumin (1.25 μ M) and β -CD (2.5 μ M) on the aggregation of α -synuclein in the presence of buffer only or cell mimicking conditions (100 g/L Dextran 40)	174
5.4	Effect of different components of the optimized concoction (2.5 mM sucrose, 2.5 μ M β -CD, and 1.25 μ M curcumin) on the aggregation of α -synuclein monitored using ThT fluorescence ($\lambda_{ex} = 430$ nm and $\lambda_{em} = 485$ nm)	175
5.5	Effect of different optimized combinations of sucrose (3.5 mM) with curcumin (1.25 μ M) and β -CD (2.5 μ M) on the aggregation of α -synuclein monitored using ThT fluorescence ($\lambda_{ex} = 430$ nm and $\lambda_{em} = 485$ nm) after 100 hrs in the presence of different concentrations of various macromolecular crowding agents	176
5.6	Effect of the optimized combination of sucrose (3.5 mM) with curcumin (1.25 μ M) and β -CD (2.5 μ M) on the disruption of preformed aggregates of α -synuclein in the presence of buffer only or cell mimicking conditions (100 g/L Dextran 40)	177
5.7	SEC analysis showing the elution profile of α -synuclein showing its inhibition of aggregation after addition of optimized concoction of sucrose (3.5 mM) with curcumin (1.25 μ M) and β -CD (2.5 μ M) to the preformed aggregates of α -synuclein	179
5.8	Transmission electron micrographs showing the effect of the optimized combination of sucrose (3.5 mM), curcumin (1.25 μ M) and β -CD (2.5 μ M) on α -synuclein	180
5.9	Effect of EGCG in combination with β -CD in the presence and absence of sucrose on the aggregation of α -synuclein monitored using ThT fluorescence ($\lambda_{ex} = 430$ nm and $\lambda_{em} = 485$ nm)	181
5.10	Effect of higher concentration of sucrose (20 mM) on the aggregation of α -synuclein in combination with different concentrations of: (a) curcumin and β -CD and (b) EGCG and β -CD	183

5.11	Schematic diagram showing the mechanism of action of the sucrose–polyphenol– β -CD combination during disaggregation	189
5.12	Complete (left) and enlarged (right) 1.8 ns snapshot from one of the molecular dynamics trajectories of the evolution of decamer fragment of heptapeptide (GNNQQNY) fibril with the polyphenol	190
Chapter 6		
6.1	Aggregation of both the globular proteins [(a) β -lactoglobulin, and (b) lysozyme] monitored using ThT fluorescence ($\lambda_{\text{ex}} = 430$ nm and $\lambda_{\text{em}} = 485$ nm) in the presence of different concentrations of macromolecular crowding agents namely Dextran 40, Dextran 6 and Ficoll 70	202
6.2	Intrinsic fluorescence emission in the presence of different concentrations of the macromolecular crowding agents namely, Dextran 40, Dextran 6 and Ficoll 70: (Column (a)) β -lactoglobulin ($\lambda_{\text{ex}} = 295$ nm and $\lambda_{\text{em}} = 328$ nm) and (Column (b)) lysozyme ($\lambda_{\text{ex}} = 295$ nm and $\lambda_{\text{em}} = 338$ nm)	204
6.3	ANS emission spectra (with an excitation of 390 nm) in presence of the globular proteins: (a) β -Lactoglobulin and (b) lysozyme, as a function of Dextran 40 as the crowding agent	206
6.4	Effect of different concentrations of the combination of curcumin and β -CD on the aggregation of globular proteins (β -lactoglobulin and lysozyme) monitored using ThT fluorescence ($\lambda_{\text{ex}} = 430$ nm and $\lambda_{\text{em}} = 485$ nm)	207
6.5	Effect of sucrose (3.5 mM) in the presence of different concentrations of curcumin and β -CD on the aggregation of globular proteins (β -lactoglobulin and lysozyme) monitored using ThT fluorescence ($\lambda_{\text{ex}} = 430$ nm and $\lambda_{\text{em}} = 485$ nm)	210
6.6	Effect of the optimized combination of sucrose with curcumin and β -CD on the disruption of preformed aggregates of globular proteins	212
6.7	Transmission electron micrographs showing the effect of the optimized combination of sucrose with curcumin and β -CD on globular proteins: (a) β -lactoglobulin and (b) lysozyme	213
6.8	Enzymatic activity analysis of lysozyme	214
6.9	Intrinsic fluorescence emission spectra (with an excitation of 295 nm) of both the disaggregated globular proteins: (a) β -lactoglobulin and (b) lysozyme	215
6.10	Effect of EGCG in combination with β -CD in the presence and absence of sucrose on the aggregation of globular proteins (β -lactoglobulin and lysozyme) monitored using ThT fluorescence ($\lambda_{\text{ex}} = 430$ nm and $\lambda_{\text{em}} = 485$ nm)	217

6.11	Fluorescence emission spectra of curcumin in the presence of: (a) β -lactoglobulin and (b) lysozyme	219
6.12	Effect of higher concentration of sucrose (20 mM) in combination with different concentrations of curcumin/EGCG and β -CD on the aggregation of β -lactoglobulin and lysozyme monitored using ThT fluorescence ($\lambda_{\text{ex}} = 430$ nm and $\lambda_{\text{em}} = 485$ nm)	222
6.13	Chemical structures of curcumin and EGCG used in this study	227
Chapter 7		
7.1	Fluorescence emission spectra (Arbitrary units, AU) of solubilized inclusion bodies of CcdB-F17P with Eudragit L-100	244
7.2	The size distribution analysis to show the binding of the protein molecules with the smart polymers with time at 25 °C by dynamic light scattering experiment	246
7.3	(A) Binding of solubilized inclusion bodies of CcdB-F17P with Eudragit L-100 at different concentrations of Eudragit L-100 at 25 °C. The protein concentration was 0.5 mg/mL in a total volume of 0.2 ml in 50 mM Tris-HCl, pH 7.5. (B) Binding of solubilized inclusion bodies of CcdB-F17P with Eudragit L-100 at different protein concentrations at 25 °C	248
7.4	(A) Fluorescence emission spectra (AU, arbitrary units) of CcdB proteins in 10 mM Tris-HCl, pH 7.5, with excitation at 280 nm using excitation and emission slit widths of 2 nm and 5 nm, respectively and (B) Far-UV CD spectra of CcdB proteins	250
7.5	ANS fluorescence emission spectra (AU, arbitrary units) of CcdB proteins with excitation at 390 nm using excitation and emission slit widths of 2 nm and 5 nm, respectively	251
7.6	SDS-PAGE analysis of the proteins refolded and purified by smart polymers from inclusion bodies	252
7.7	(A) Fluorescence emission spectra (AU, arbitrary units) of thioredoxin proteins, (B) ANS fluorescence emission spectra (AU, arbitrary units) of thioredoxin proteins, and (C) Far-UV CD spectra of thioredoxin proteins	254
7.8	(A) Fluorescence emission spectra (AU, arbitrary units) of CD4D12, (B) ANS fluorescence emission spectra (AU, arbitrary units) of CD4D12, and (C) Far-UV CD spectra of CD4D12	256
7.9	The size distribution analysis to show the binding of the protein molecules with the smart polymers with time at 25 °C by dynamic light scattering experiment for: (A) MBP224D with cationic starch and (B) ScFv b12 with Protanal LF	257

7.10	(A) Fluorescence based assay of refolded MBP mutants and (B) ANS fluorescence emission spectra (AU, arbitrary units) of MBP proteins	259
7.11	(A) Fluorescence emission spectra (AU, arbitrary units) of refolded ScFv b12 and ScFab b12 and (B) Far-UV CD spectra of ScFv b12 and ScFab b12	261
7.12	(A) Unbound protein remaining in the supernatant after incubation of the smart polymers for different time intervals with the solubilized inclusion bodies, (B) Effect of incubation time of the protein with the smart polymer on the recovery of proteins, and (C) Far-UV CD spectra of recovered CcdB-F17P from Eudragit L-100 at different time intervals	263
Supplementary Information		
S4.1	Aggregation profiles of α -synuclein monitored using CR absorbance at 540 nm in the presence of different concentrations of the macromolecular crowding agents namely, Dextran 40, Dextran 6 and Ficoll 70	280
S4.2	Effect of different polyphenols with various concentrations on the aggregation of α -synuclein monitored using CR absorbance at 540 nm in the presence of Dextran 40 (100 g/L) as a macromolecular crowding agent	281
S4.3	Effect of different polyphenols in combination with β -CD on the aggregation of α -synuclein monitored using ThT fluorescence ($\lambda_{\text{ex}} = 430$ nm and $\lambda_{\text{em}} = 485$ nm) in the presence of Dextran 6 (100 g/L) as a macromolecular crowding agent	282
S4.4	Effect of different polyphenols in combination with β -CD on the aggregation of α -synuclein monitored using ThT fluorescence ($\lambda_{\text{ex}} = 430$ nm and $\lambda_{\text{em}} = 485$ nm) in the presence of Ficoll 70 (100 g/L) as a macromolecular crowding agent	283
S4.5	Effect of different optimized combinations of polyphenols with β -CD on the aggregation of α -synuclein monitored using ThT fluorescence ($\lambda_{\text{ex}} = 430$ nm and $\lambda_{\text{em}} = 485$ nm) after 100 hrs in the presence of different concentrations of various macromolecular crowding agents	284
S4.6	Disaggregation of preformed aggregates of α -synuclein in the presence and absence of different macromolecular crowding agents monitored using CR absorbance at 540 nm	285
S4.7	Disaggregation of preformed aggregates of α -synuclein in the presence of Dextran 40 as a macromolecular crowding agent with a higher concentration of 200 g/L in the: (a) presence of 7.5% (v/v) ethanol and (b) absence of ethanol	286
S4.8	SEC analysis showing elution profiles for disaggregation of α -synuclein	287

S4.9	TEM images of α -synuclein for disaggregation of preformed aggregates of α -synuclein in the presence	288
S5.1	Secondary structural analysis of α -synuclein using far UV CD spectroscopy in: (a) buffer only and (b) cell mimicking conditions (100 g/L Dextran 40)	289
S5.2	SEC analysis showing the elution profile of α -synuclein	290
S6.1	Intrinsic fluorescence emission spectra (with an excitation of 295 nm) of the globular proteins in presence of different concentrations of the macromolecular crowding agents	291
S6.2	Effect of different optimized combination curcumin with β -CD on the aggregation of globular proteins (β -lactoglobulin and lysozyme) monitored using ThT fluorescence ($\lambda_{\text{ex}} = 430$ nm and $\lambda_{\text{em}} = 485$ nm) after 300 min in the presence of different concentrations of various macromolecular crowding agents	292
S6.3	Effect of different optimized combination of sucrose, curcumin with β -CD on the aggregation of globular proteins (β -lactoglobulin and lysozyme) monitored using ThT fluorescence ($\lambda_{\text{ex}} = 430$ nm and $\lambda_{\text{em}} = 485$ nm) after 300 min in the presence of different concentrations of various macromolecular crowding agents	293

LIST OF TABLES

Table No.	Table Title	Page No.
Chapter 1		
1.1	Human pathological disorders due to protein aggregation	2
1.2	Different types of protein aggregates	7
1.3	Different types of cyclodextrins	32
Chapter 4		
4.1	Kinetic parameters obtained for aggregation α -synuclein in the presence of different concentrations of crowding agents with or without 7.5% (v/v) ethanol	130
4.2	Kinetic parameters obtained as a function of ethanol concentration for the aggregation of α -synuclein in the presence of Dextran 40 (100 g/L) as a macromolecular crowding agent	131
4.3	Effective concentrations of polyphenols (in the absence and presence of β -CD) required for complete inhibition of aggregation of α -synuclein in buffer only or in the presence of macromolecular crowding agents	133
4.4	Kinetic parameters obtained for disaggregation (of preformed aggregates) of α -synuclein in the presence of three different macromolecular crowding agents (Dextran 40, Dextran 6 and Ficoll 70) at a concentration of 100 g/L by the different optimized polyphenol- β -CD combinations	138
Chapter 5		
5.1	Kinetic data for the inhibition of aggregation of α -synuclein by different concentrations of the two osmolytes, glucose and sucrose	170
5.2	Kinetic data for the inhibition of aggregation of α -synuclein by different concentrations of osmolytes (glucose and sucrose) in combination with curcumin (1.25 μ M) and β -CD (2.5 μ M)	173
5.3	Kinetic data for the inhibition of aggregation of α -synuclein by different concentrations of sucrose in combination with curcumin (1.25 μ M) and β -CD (2.5 μ M) under cell mimicking conditions (100 g/L Dextran 40)	174
5.4	Parameters obtained from fitting the disaggregation profiles of preformed aggregates of α -synuclein by the optimized combination of sucrose (3.5 mM), curcumin (1.25 μ M) and β -CD (2.5 μ M) in the presence of buffer only or cell mimicking conditions (100 g/L Dextran 40)	178

5.5	Parameters obtained from fitting the aggregation profiles for the inhibition of aggregation of α -synuclein by EGCG and β -CD in the absence and presence of sucrose	182
5.6	Concentrations of curcumin and β -CD required for complete inhibition of protein aggregation in the presence of different concentrations of sucrose	184
Chapter 6		
6.1	Properties of the two globular proteins (β -lactoglobulin and lysozyme) used in current study and their comparison with α -synuclein	200
6.2	Kinetic parameters for aggregation of globular proteins (β -lactoglobulin and lysozyme) as a function of concentrations of various crowding agents (Dextran 40, Dextran 6 and Ficoll 70)	203
6.3	Kinetic parameters for the inhibition of aggregation of the globular proteins (β -lactoglobulin and lysozyme) by different concentrations of curcumin- β -CD combination	208
6.4	Kinetic parameters for the inhibition of aggregation of globular proteins (β -lactoglobulin and lysozyme) by 3.5 mM sucrose in the presence of difference concentrations of curcumin and β -CD	211
6.5	Kinetic data for the inhibition of aggregation of β -lactoglobulin and lysozyme by EGCG and β -CD in the presence and absence of sucrose	218
6.6	(a) Concentrations of curcumin and β -CD required for complete inhibition of protein aggregation in the presence of different concentrations of sucrose. (b) Concentrations of EGCG and β -CD required for complete inhibition of protein aggregation in the presence of different concentrations of sucrose	221
Chapter 7		
7.1	High-throughput screening of the affinity ligand (smart polymer) in 96-well plate for appropriate refolding of the proteins	239
7.2	Properties of the different smart polymers used	240
7.3	Dissociation of bound proteins from Eudragit L-100 by different dissociating agents	243
7.4	Melting temperature (T_m) and other physicochemical properties of different proteins refolded by affinity precipitation and their comparison with soluble native (wild type) proteins	247
7.5	Insulin aggregation assay for thioredoxin proteins	255
7.6	Refolding yields (mg/L of culture) ^a of proteins refolded by affinity precipitation with smart polymers	261

Supplementary Information		
S4.1	Kinetic parameters obtained for the dose dependent disaggregation of preformed aggregates of α -synuclein as a function of increasing concentrations of polyphenols with β -CD	279
S7.1	Secondary structure analysis of the CcdB-F17P recovered from the Eudragit L-100 after incubation with varying time intervals	294
S7.2	Secondary structure analysis of the unbound CcdB-F17P recovered in the supernatant after precipitation of the Eudragit L-100 with bound protein with varying time intervals	295